Chargement en cours...
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
Programmed death-1 inhibitors are approved for patients with relapsed or refractory classic Hodgkin lymphoma (RRcHL). We present the 2-year follow-up of the phase 2 KEYNOTE-087 study of pembrolizumab in 210 patients, based on HL progression after autologous stem cell transplantation (ASCT) and subse...
Enregistré dans:
| Publié dans: | Blood |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Hematology
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6776792/ https://ncbi.nlm.nih.gov/pubmed/31409671 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019000324 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|